Clinical diagnostic services
COLARIS® & COLARIS AP®
Tests to diagnose hereditary colorectal cancer syndromes
Proactive cancer management through early risk identification
COLARIS® assesses an individual's risk of developing colorectal, endometrial and other related cancers based on the detection of mutations in the MLH1, MSH2, and MSH6 genes. This hereditary cancer syndrome is known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC, or Lynch syndrome).
COLARIS AP® assesses an individual's risk of developing colorectal polyps and cancer based on detection of mutations in the APC and MYH genes. These hereditary cancer syndromes are known as familial adenomatous polyposis (FAP/AFAP) and MYH – associated polyposis (MAP).
Why choose COLARIS® or COLARIS AP® testing?
COLARIS® & COLARIS AP® genetic testing enable the Clinician to:
- Take a proactive management approach with clearly identified at-risk patients
- Avoid unnecessary interventions in family members who have not inherited a known familial mutation
- Target increased surveillance and other interventions to individuals with a mutation – maximising patient care while increasing clinical efficiency
- Counsel patients and family members on the underlying cause of cancer, in the case of a positive result
- Significantly improve patient outcomes
Who should be tested?
The following may benefit from either COLARIS® and/or COLARIS AP® testing:
Candidates for HNPCC testing with COLARIS®
Personal or family history of:
- Colorectal cancer <50, or
- Endometrial Cancer <50, or
- 2 or more HNPCC* cancers in an individual or family
- including colorectal, endometrial, ovarian and gastric
Candidates for FAP/AFAP/MAP testing with
COLARIS AP®
- Personal or family history of:
- 10 or more cumulative colorectal adenomas, and/or,
- Colorectal cancer <50
Myriad, COLARIS AP and COLARIS are either trademarks or registered trademarks of Myriad Genetics, Inc in the United States and other jurisdictions
Product
sheet PDF
Genetic test for adenomatous polyposis syndromes
Product
sheet PDF
genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)
What is the test?
Both COLARIS® & COLARIS AP® are genetic tests that require only a blood sample to determine whether a patient carries gene mutations, indicating a predisposition to colorectal cancer. This is the most accurate clinical test available to detect gene mutations that increase the risk of developing colorectal cancer.
From receipt of the patient samples at Myriad’s testing laboratory, a report will be sent within 21 working days. If results are required urgently a rapid service is also available with gene sequence analysis results within 12 working days.
